<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926887</url>
  </required_header>
  <id_info>
    <org_study_id>EBA-001</org_study_id>
    <nct_id>NCT00926887</nct_id>
  </id_info>
  <brief_title>Low Level Laser Therapy to Reduce Pain After Breast Augmentation Surgery</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Evaluation of the Effect of the Erchonia(R) EML Laser on Reducing Pain Following Breast Augmentation Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erchonia Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erchonia Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the clinical study was to see if applying low level laser light therapy to the
      breasts during breast implant surgery could lessen pain experienced by 24 hours after the
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Substantial pain, discomfort and swelling following breast augmentation surgery is not
      uncommon. The ability of low level laser therapy to reduce swelling and inflammation that
      subsequently reduces pain has been well documented. This study aimed to evaluate the ability
      of low level laser therapy to reduce post-operative pain and swelling for individuals
      undergoing bilateral breast augmentation surgery, by 24 hours post-surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Scored Less Than 30 on the 0-100 Visual Analog Scale (VAS)for Pain 24 Hours Post-operative.</measure>
    <time_frame>24 hours post-operative</time_frame>
    <description>Self-reported Degree of Pain rating using the standardized 0-100 Visual Analog Scale (VAS) scale provided at 24 hours post-implant procedure, at which time the subject will not have taken any pain medication for at least four hours. The VAS ratings range from 0 to 100, where '0' represents 'no pain at all' and '100' represents 'worst pain imaginable.' A VAS of 30 is indicated as a cutoff threshold for 'success.' Participants who recorded a VAS rating of less than 30 were considered study 'successes' and are reported below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-reported Pain Rating on the 0-100 VAS 24 Hours Post-operative.</measure>
    <time_frame>24 hours</time_frame>
    <description>Self-reported Degree of Pain rating using the standardized 0-100 VAS scale provided at 24 hours post-implant procedure, at which time the subject will not have taken any pain medication for at least four hours. VAS values range from '0' representing 'no pain at all' to '100' representing 'worst pain imaginable.'</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Swelling Evaluation Through Length by Width Breast Diameter Measurements</measure>
    <time_frame>immediately, 24 hours &amp; 7 days post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported Degree of Pain Rating in the Breasts Area.</measure>
    <time_frame>24 hours, 7 days, 14 days &amp; 28 days post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Pain Management Medication Post-surgically.</measure>
    <time_frame>Through the 1st 7 post-operative days.</time_frame>
    <description>Average number of rescue pain medication doses consumed across the 1st 7 post-operative days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hydration Level Assessment</measure>
    <time_frame>immediately, 24 hours &amp; 7 days post surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection Evaluation</measure>
    <time_frame>24 hours &amp; 7 days post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound Healing Evaluation According to the Modified Hollander Cosmesis Scale</measure>
    <time_frame>7 days post surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo Laser</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo Laser is an inactive light</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erchonia EML Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Erchonia EML Laser uses two 7mW red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Erchonia(R) EML Laser</intervention_name>
    <description>Low level laser red light of 635 nm and delivering 1.5 joules/cm2.</description>
    <arm_group_label>Erchonia EML Laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Laser</intervention_name>
    <description>Inactive light</description>
    <arm_group_label>Placebo Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suitability for breast augmentation surgery based on the need for correction of a
             congenital deformity or condition such as: Amastia, Hypomastia, Hypoplasia, Pectus
             Carinatum, Pectus Excavatum, OR a cosmetic breast enhancement indication, including:
             Augmentation to increase breast size, correction of ptotic (drooping) or pendulous
             (sagging) breasts, recontouring to obtain enhanced breast shape.

          -  Bilateral breast augmentation indication only.

          -  18 to 55 years, inclusive.

          -  Female, only.

          -  Willingness, and ability, to refrain from consuming over-the-counter and/or
             prescription medications for the indication of the relief of pain and/or swelling,
             including any non-steroidal anit-inflammatory drugs (NSAIDs), from 48 hours
             immediately prior to the laser-assisted breast implant procedure through to one week
             post-procedure.

        Exclusion Criteria:

          -  Breast augmentation procedures indicated for the purpose of breast reconstruction
             following mastectomy or an injury due to severe trauma.

          -  Presence of a specific connective tissue disorder.

          -  Inadequate tissue available to cover the implants.

          -  Consumption of any one or more of narcotics, opiates, and/or steroids.

          -  Inability to consume the following medications post-operatively due to allergy,
             intolerance, or any other reason:

             (i) Pain medication for the relief of post-operative pain of Lortab 10/500 or another
             drug within the combination narcotic analgesic drug category within which Lortab
             falls.

        (ii) Antibiotic medication for reducing the risk of post-operative infection of Keflex 500
        mg or Cipro 500 mg or another drug within the broad-spectrum antibiotic drug category
        within which Keflex and Cipro fall.

          -  Developmental disability or cognitive impairment that impacts a subject's ability to
             read and/or to understand the content of the informed consent form, and/or impacts a
             subject's ability to read and /or to understand and/or to complete the required case
             report form information for the clinical study.

          -  Significant psychological disorder(s) for which treatment has become necessary,
             including anxiety and depression; psychiatric hospitalization.

          -  Pregnancy or lactation.

          -  Prior surgery to the breast area, or to the area of the intended incision.

          -  Infection or wound in the intended areas of treatment.

          -  Involvement in litigation and/or receiving disability benefits related to the
             subject's breast(s).

          -  Participation in research over the preceding 90 days.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert F Jackson, MD, FACS</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Gregory Roche, DO</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Thomas L Jackson, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <link>
    <url>http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=25548</url>
    <description>FDA 510(k)#K072206 clearance listing resulting from the outcome of this study</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2009</study_first_posted>
  <results_first_submitted>June 26, 2009</results_first_submitted>
  <results_first_submitted_qc>June 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 6, 2011</results_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was from 9/30/05 - 6/28/07 at private practice test site locations.</recruitment_details>
      <pre_assignment_details>There were no significant events or approaches for the study following participant enrollment and prior to group assignment. All enrolled participants proceeded to group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Laser</title>
          <description>inactive light</description>
        </group>
        <group group_id="P2">
          <title>Erchonia(R) EML Laser</title>
          <description>The Erchonia(R) EML Laser uses two 7mw red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Laser</title>
          <description>inactive light</description>
        </group>
        <group group_id="B2">
          <title>Erchonia(R) EML Laser</title>
          <description>The Erchonia(R) EML Laser uses two 7mw red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Scored Less Than 30 on the 0-100 Visual Analog Scale (VAS)for Pain 24 Hours Post-operative.</title>
        <description>Self-reported Degree of Pain rating using the standardized 0-100 Visual Analog Scale (VAS) scale provided at 24 hours post-implant procedure, at which time the subject will not have taken any pain medication for at least four hours. The VAS ratings range from 0 to 100, where '0' represents 'no pain at all' and '100' represents 'worst pain imaginable.' A VAS of 30 is indicated as a cutoff threshold for 'success.' Participants who recorded a VAS rating of less than 30 were considered study 'successes' and are reported below.</description>
        <time_frame>24 hours post-operative</time_frame>
        <population>ITT Analysis with LOCF technique employed, as applicable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Laser</title>
            <description>inactive light</description>
          </group>
          <group group_id="O2">
            <title>Erchonia(R) EML Laser</title>
            <description>The Erchonia(R) EML Laser uses two 7mw red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Scored Less Than 30 on the 0-100 Visual Analog Scale (VAS)for Pain 24 Hours Post-operative.</title>
          <description>Self-reported Degree of Pain rating using the standardized 0-100 Visual Analog Scale (VAS) scale provided at 24 hours post-implant procedure, at which time the subject will not have taken any pain medication for at least four hours. The VAS ratings range from 0 to 100, where '0' represents 'no pain at all' and '100' represents 'worst pain imaginable.' A VAS of 30 is indicated as a cutoff threshold for 'success.' Participants who recorded a VAS rating of less than 30 were considered study 'successes' and are reported below.</description>
          <population>ITT Analysis with LOCF technique employed, as applicable.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swelling Evaluation Through Length by Width Breast Diameter Measurements</title>
        <time_frame>immediately, 24 hours &amp; 7 days post surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-reported Degree of Pain Rating in the Breasts Area.</title>
        <time_frame>24 hours, 7 days, 14 days &amp; 28 days post surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Pain Management Medication Post-surgically.</title>
        <description>Average number of rescue pain medication doses consumed across the 1st 7 post-operative days.</description>
        <time_frame>Through the 1st 7 post-operative days.</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Laser</title>
            <description>inactive light</description>
          </group>
          <group group_id="O2">
            <title>Erchonia(R) EML Laser</title>
            <description>The Erchonia(R) EML Laser uses two 7mw red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Pain Management Medication Post-surgically.</title>
          <description>Average number of rescue pain medication doses consumed across the 1st 7 post-operative days.</description>
          <population>ITT with LOCF</population>
          <units>medication doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.26" spread="8.89"/>
                    <measurement group_id="O2" value="18.43" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t=-2.711; df=102; p&lt;0.01</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hydration Level Assessment</title>
        <time_frame>immediately, 24 hours &amp; 7 days post surgery.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infection Evaluation</title>
        <time_frame>24 hours &amp; 7 days post surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wound Healing Evaluation According to the Modified Hollander Cosmesis Scale</title>
        <time_frame>7 days post surgery</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Self-reported Pain Rating on the 0-100 VAS 24 Hours Post-operative.</title>
        <description>Self-reported Degree of Pain rating using the standardized 0-100 VAS scale provided at 24 hours post-implant procedure, at which time the subject will not have taken any pain medication for at least four hours. VAS values range from '0' representing 'no pain at all' to '100' representing 'worst pain imaginable.'</description>
        <time_frame>24 hours</time_frame>
        <population>Intention to treat (ITT) analysis with imputation technique of Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Laser</title>
            <description>inactive light</description>
          </group>
          <group group_id="O2">
            <title>Erchonia(R) EML Laser</title>
            <description>The Erchonia(R) EML Laser uses two 7mw red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Pain Rating on the 0-100 VAS 24 Hours Post-operative.</title>
          <description>Self-reported Degree of Pain rating using the standardized 0-100 VAS scale provided at 24 hours post-implant procedure, at which time the subject will not have taken any pain medication for at least four hours. VAS values range from '0' representing 'no pain at all' to '100' representing 'worst pain imaginable.'</description>
          <population>Intention to treat (ITT) analysis with imputation technique of Last Observation Carried Forward (LOCF).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.78" spread="24.62"/>
                    <measurement group_id="O2" value="21.40" spread="20.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=102, t=-3.44</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Laser</title>
          <description>inactive light</description>
        </group>
        <group group_id="E2">
          <title>Erchonia(R) EML Laser</title>
          <description>The Erchonia(R) EML Laser uses two 7mw red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elvira Walls, Clinical Consultant</name_or_title>
      <organization>Regulatory Insight, Inc.</organization>
      <phone>615-712-9743</phone>
      <email>elvira@reginsight.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

